| Literature DB >> 33637415 |
Ashish Verma1, Ankit B Patel2.
Abstract
Hemodynamic alterations, metabolic dysfunction, inflammation, and fibrosis are the main drivers of diabetic kidney disease (DKD) progression. Targeting inflammation and fibrosis as a driver, the FIDELIO-DKD (Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes) trial reported by Bakris et al. provides evidence of a new therapeutic class for treating DKD.Entities:
Keywords: FIDELIO-DKD; diabetic kidney disease; finerenone; non-steroidal mineralocorticoid receptor blocker
Mesh：
Substances：
Year: 2021 PMID： 33637415 DOI： 10.1016/j.tem.2021.02.002
Source DB: PubMed Journal: Trends Endocrinol Metab ISSN： 1043-2760 Impact factor: 12.015